The sigma-1 receptor agonist 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) protects against newborn excitotoxic brain injury by stabilizing the mitochondrial membrane potential in vitro and inhibiting microglial activation in vivo.

Abstract

Premature birth represents a clinical situation of risk for brain injury. The diversity of pathophysiological processes complicates efforts to find effective therapeutic strategies. Excitotoxicity is one important factor in the pathogenesis of preterm brain injury. The observation that sigma-1 receptor agonists possess neuroprotective potential, at least partly mediated by a variety of anti-excitotoxic mechanisms, has generated great interest in targeting those receptors to counteract brain injury. The objective of this study was to evaluate the effect of the highly specific sigma-1 receptor agonist, 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) to protect against excitotoxic developmental brain injury in vivo and in vitro. Primary hippocampal neurons were pre-treated with PPBP before glutamate was applied and subsequently analyzed for cell death (PI/calcein AM), mitochondrial activity (TMRM) and morphology of the neuronal network (WGA) using confocal microscopy. Using an established neonatal mouse model we also determined whether systemic injection of PPBP significantly attenuates excitotoxic brain injury. PPBP significantly reduced neuronal cell death in primary hippocampal neurons exposed to glutamate. Neurons treated with PPBP showed a less pronounced loss of mitochondrial membrane potential and fewer morphological changes after glutamate exposure. A single intraperitoneal injection of PPBP given one hour after the excitotoxic insult significantly reduced microglial cell activation and lesion size in cortical gray and white matter. The present study provides strong support for the consideration of sigma-1 receptor agonists as a candidate therapy for the reduction of neonatal excitotoxic brain lesions and might offer a novel target to counteract developmental brain injury.

• Authors: Karina Wegleiter, Martin Hermann, Anna Posod, Karina Wechselberger, Ruslan I Stanika, Gerald J Obermair, Ursula Kiechl-Kohlendorfer, Martina Urbanek, Elke Griesmaier
• Journal: Experimental neurology (Exp Neurol) Vol. 261 Pg. 501-9 (Nov 2014) ISSN: 1090-2430 [Electronic] United States
• PMID: 25111531 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Chemical References

• Apoptosis Inducing Factor
• Excitatory Amino Acid Agonists
• Glycoproteins
• Receptors, sigma
• isolectin B4-binding glycoprotein, mouse
• sigma-1 receptor
• 4-phenyl-1-(4-phenylbutyl)piperidine
• Ibotenic Acid
• Glutamic Acid
• Caspase 3
• Haloperidol

Topics

• Animals
• Animals, Newborn
• Apoptosis (drug effects)
• Apoptosis Inducing Factor (metabolism)
• Brain Injuries (chemically induced, prevention & control)
• Caspase 3 (metabolism)
• Disease Models, Animal
• Excitatory Amino Acid Agonists (toxicity)
• Glutamic Acid (pharmacology)
• Glycoproteins (metabolism)
• Haloperidol (analogs & derivatives, therapeutic use)
• Hippocampus (cytology)
• Ibotenic Acid (toxicity)
• Membrane Potential, Mitochondrial (drug effects)
• Mice
• Microglia (drug effects)
• Neurons (drug effects, physiology)
• Receptors, sigma (agonists)
• Statistics, Nonparametric